Industry update Low-THC weed led to poor results in major PTSD study US researchers seek DEA to permit potent pot production after long-awaited FDA-backed study shows weak weed ineffective at treating PTSD Jared GnamMarch 30, 2021
Industry update Charlotte’s Web bounces back in Q4 American CBD market leader reports 2020 sales of US$95.2M and positive results for a third-party liver toxicity study Jared GnamMarch 25, 2021
Canada Aloe vera extract producer funds McGill CBD pain research Maine-based Desert Harvest is working with university researchers to see if its CBD-aloe vera formula can treat pain more safely and effectively than opioids Jared GnamFebruary 3, 2021
Industry update US FDA unveils plan to gather ‘real-world’ data to fill CBD research gaps After two years of delaying regulations, the agency looks to improve data-gathering methods on CBD product safety Jared GnamJanuary 11, 2021
Industry update Dousing strawberries in CBD oil reduces mould, extends shelf life: study Research from the University of South Florida suggests CBD has promising potential as an antimicrobial treatment for fresh produce Jared GnamDecember 10, 2020
Industry update Worm study shows CBD may extend life But Canopy Growth's new research reveals why cannabidiol science has a ways to go before US regulators deem it safe Jared GnamNovember 23, 2020
The weed wire FDA’s new draft guidelines could speed up CBD drug approvals As industry players await full regulations, the US federal agency continues to slowly open up the CBD market Jared GnamSeptember 29, 2020
The weed wire Canopy launches Martha Stewart CBD line in cluttered US market Canadian weed titan hopes Stewart's celebrity power will catapult it above the 3,000 brands in the US CBD space Jared GnamSeptember 10, 2020
Cannabis Company study suggests inhalation of CBD safer than ingestion Tetra Bio-Pharma's results relate to other findings that high doses of CBD can cause toxicity in the liver when ingested Nick LabaAugust 28, 2020
COVID-19 Revive Therapeutics approved by FDA for Phase 3 trial of possible Covid-19 treatment Shares of the novel drug developer jumped 68% Friday on the news Jared GnamJuly 31, 2020